A Science and Technology Blog
The Pune-based Serum Institute of India has already begun manufacturing the Oxford vaccine (ChAdOx1 nCoV-19) for novel coronavirus. The company intends to manufacture two-three million doses by end-August. The Pune-based…
With the pandemic raging across many countries and the demand for a safe, efficacious vaccine being huge, availability of an indigenous vaccine will mean guaranteed availability for Indians, while a…
The results of the Phase-1 clinical trial of the Oxford vaccine (ChAdOx1 nCoV-19) to prevent infection by novel coronavirus are expected by the first week of July. Serum Institute of…
Serum Institute is optimistic that its pneumococcal vaccine will be available in India by June 2020. The vaccine is yet to be approved by the DCGI. But phase-3 trial data…
WHO has prequalified Pune-based Serum Institute’s pneumococcal conjugate vaccine made of 10 serotypes that are widely prevalent and cause pneumonia in Latin America, Africa and Asia. The vaccine will cost…
In Phase III trial, Serum Institute’s rotavirus vaccine (ROTASIIL) was found to have nearly 55% efficacy against the very severe form of rotavirus diarrhoea and nearly 39% efficacy in severe…
In June this year, the Pune-based Serum Institute of India Pvt Limited will begin a Phase II/III vaccine trial for tuberculosis using a novel, recombinant BCG (bacillus Calmette-Guérin) vaccine. The…
Buoyed by the successful elimination of polio six years ago and maternal and neonatal tetanus and yaws in 2016, India has set an ambitious target of eliminating measles and controlling…
